Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Zydus and Dr. Reddy’s Collaborate to Co-Market Pertuzumab Biosimilar, Vital for Breast Cancer Treatment in India

NextEdge Admin

29 Jun 2024

3 min 3 sec

Zydus Lifesciences Limited and Dr. Reddy’s Laboratories Ltd. have entered a pivotal licensing agreement to co-market a biosimilar of Pertuzumab in India, a crucial treatment for HER2 positive breast cancer patients. Developed internally by Zydus' research team at the Zydus Research Centre (ZRC), this biosimilar will be marketed by Zydus as Sigrima™ and by Dr. Reddy’s as Womab®. The collaboration grants Dr. Reddy’s semi-exclusive rights to co-market the product alongside Zydus.

Pertuzumab, an anti-HER2 monoclonal antibody, plays a critical role in inhibiting HER2-mediated cell proliferation in HER2 positive breast cancers. It is recommended for use in combination with other therapies such as trastuzumab and chemotherapy, impacting outcomes by reducing tumor size, preserving breast tissue, and extending patient survival. Despite its significant benefits, access to this combination therapy is limited, reaching less than 5% of eligible patients.

The introduction of Pertuzumab biosimilar by Zydus and Dr. Reddy’s aims to broaden access to this essential treatment across India. Zydus, known for its comprehensive cancer care therapies including Vivitra™ (trastuzumab biosimilar) and Ujvira™ (antibody drug conjugate biosimilar of trastuzumab emtansine), emphasizes its commitment to enhancing patient outcomes in HER2-positive breast cancer.

Dr. Reddy’s, a global pharmaceutical leader in oncology, views this collaboration as a strategic step to bolster its portfolio in breast cancer care. Already offering biosimilar trastuzumab (Hervycta®), the addition of Pertuzumab biosimilar (Womab®) underscores their dedication to advancing standard of care for HER2 positive patients in India.

With an estimated 2,30,000 new cases of breast cancer expected in 2025, approximately 25% of which are HER2-positive, the availability of Pertuzumab biosimilar is poised to make a significant impact. Both companies express optimism about the partnership's potential to improve treatment accessibility and patient outcomes in the fight against HER2 positive breast cancer, aligning with their shared mission to expand therapeutic options and elevate standards of cancer care in India.